The fusion between Swedish pharmaceutical company ... to avoid confusion with Sanofi-Aventis’ diuretic, Lasix (furosemide). However, this new name has since caused confusion between Prilosec ...

Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

Also Read: Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood ...

After more than a decade in the United States, nuclear physicist Liu Chang, whose research has been crucial in the journey to achieve fusion energy, has left Princeton University for a position at ...

Proxima Fusion, a two-year-old German nuclear fusion startup, has published plans for a working fusion power plant in a peer-reviewed journal, in what is being touted as an important change in ...